MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

RMD · NYSE

ResMed Inc.

Health Care · Medical/Dental Instruments

Reference price$208.96As of Jul 28, 2026
Market capitalization$30.31B
52-week range$180.27–$293.81
S&P 500 portfolio weight0.05%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$220.00+5.3% vs. reference
Average$240.73+15.2% vs. reference
High$320.00+53.1% vs. reference
4 Buy9 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 6, 2026Jun 2026
Consensus EPS$2.905 estimates
Expected range$2.86–$2.95Low to high EPS
Jun 2026$11.14Street EPS consensus
Jun 2027$12.05Street EPS consensus
Jun 2028$13.10Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Jun 30, 2025.

MetricCurrentPrior
Revenue+9.8% YoY$5.15B$4.69B
Operating income$1.69B$1.32B
Net income$1.4B$1.02B
Operating cash flow$1.75B$1.4B
Capital expenditures($0.09B)($0.1B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

BNK Invest

Raymond James Financial Moves Up In Market Cap Rank, Passing ResMed

Zacks

Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care

RTTNews

Resmed To Sell MatrixCare Business To Frazier In $490 Million All-Cash Transaction

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.